Skip to main content

Pillar Biosciences, Illumina Partner on IVD Development

NEW YORK (GenomeWeb) – Cancer diagnostics firm Pillar Biosciences has partnered with Illumina to develop next-generation sequencing-based in vitro diagnostics, the companies announced today.

Under the terms of the deal, Pillar will use its stem loop inhibition-mediated amplification (SLIMamp) technology — which is designed for amplifying overlapping or tiled amplicons in a single multiplex PCR reaction — to develop diagnostics that run on Illumina's MiSeqDx instrument.

Additional terms were not disclosed.

"The combination of two state-of the-art NGS technologies, SLIMamp and MiSeqDx, is enabling affordable precision medicine," Pillar CEO Gang Song said in a statement. "SLIMamp library preparation combined with MiSeqDx makes NGS accessible to clinical laboratories."

SLIMamp was described earlier this year by Pillar researchers in PLoS One.


The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.